CRISPR Therapeutics (NASDAQ:CRSP) Director Kurt Von Emster sold 650,000 shares of the stock in a transaction that occurred on Monday, May 14th. The stock was sold at an average price of $54.39, for a total transaction of $35,353,500.00. Following the sale, the director now owns 5,629 shares in the company, valued at approximately $306,161.31. The transaction was disclosed in a document filed with the SEC, which is available at this link.

Kurt Von Emster also recently made the following trade(s):

  • On Friday, May 11th, Kurt Von Emster sold 250,000 shares of CRISPR Therapeutics stock. The stock was sold at an average price of $52.84, for a total transaction of $13,210,000.00.

Shares of CRISPR Therapeutics opened at $65.40 on Friday, MarketBeat reports. CRISPR Therapeutics has a fifty-two week low of $56.38 and a fifty-two week high of $59.00. The company has a market capitalization of $2.73 billion, a price-to-earnings ratio of -38.25 and a beta of 3.58.

CRISPR Therapeutics (NASDAQ:CRSP) last issued its earnings results on Wednesday, May 9th. The company reported ($0.62) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.67) by $0.05. CRISPR Therapeutics had a negative net margin of 189.60% and a negative return on equity of 35.18%. The firm had revenue of $1.36 million for the quarter, compared to analyst estimates of $3.64 million. During the same quarter last year, the business posted ($0.54) earnings per share. The company’s quarterly revenue was down 49.6% on a year-over-year basis. equities research analysts expect that CRISPR Therapeutics will post -2.6 EPS for the current fiscal year.

CRSP has been the topic of several analyst reports. Goldman Sachs initiated coverage on shares of CRISPR Therapeutics in a research report on Friday, April 6th. They set a “buy” rating and a $86.00 price target on the stock. SunTrust Banks upgraded shares of CRISPR Therapeutics from a “hold” rating to a “buy” rating in a research report on Tuesday, January 23rd. BidaskClub lowered shares of CRISPR Therapeutics from a “strong-buy” rating to a “buy” rating in a research report on Tuesday, April 24th. Zacks Investment Research upgraded shares of CRISPR Therapeutics from a “hold” rating to a “buy” rating and set a $58.00 target price on the stock in a research report on Friday, May 11th. Finally, Chardan Capital raised their target price on shares of CRISPR Therapeutics from $25.00 to $72.50 and gave the company a “buy” rating in a research report on Tuesday. Four analysts have rated the stock with a hold rating, seven have assigned a buy rating and one has assigned a strong buy rating to the stock. CRISPR Therapeutics currently has a consensus rating of “Buy” and a consensus price target of $64.28.

A number of institutional investors have recently modified their holdings of CRSP. Versant Venture Management LLC acquired a new position in shares of CRISPR Therapeutics during the first quarter worth $210,551,000. NEA Management Company LLC lifted its holdings in shares of CRISPR Therapeutics by 8.2% during the first quarter. NEA Management Company LLC now owns 3,484,464 shares of the company’s stock worth $159,275,000 after purchasing an additional 263,736 shares during the period. Farallon Capital Management LLC acquired a new position in shares of CRISPR Therapeutics during the fourth quarter worth $20,160,000. Franklin Resources Inc. lifted its holdings in shares of CRISPR Therapeutics by 8.9% during the fourth quarter. Franklin Resources Inc. now owns 794,533 shares of the company’s stock worth $18,656,000 after purchasing an additional 65,200 shares during the period. Finally, Global Thematic Partners LLC lifted its holdings in shares of CRISPR Therapeutics by 11.2% during the fourth quarter. Global Thematic Partners LLC now owns 633,452 shares of the company’s stock worth $14,873,000 after purchasing an additional 63,611 shares during the period. Hedge funds and other institutional investors own 36.73% of the company’s stock.

CRISPR Therapeutics Company Profile

CRISPR Therapeutics AG, a gene editing company, focuses on developing transformative gene-based medicines for the treatment of serious human diseases using its regularly interspaced short palindromic repeats associated protein-9 (CRISPR/Cas9) gene-editing platform in Switzerland. Its lead product candidate is CTX001, which targets sickle cell disease and beta-thalassemia with an ex vivo approach whereby cells are harvested from a patient, treated with a CRISPR/Cas9-based therapeutic and reintroduced into the patient.

Insider Buying and Selling by Quarter for CRISPR Therapeutics (NASDAQ:CRSP)

Receive News & Ratings for CRISPR Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CRISPR Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.